KR20140096771A - Pharmaceutical composition comprising Platycodin grandiflorum extract containing platycodin D - Google Patents
Pharmaceutical composition comprising Platycodin grandiflorum extract containing platycodin D Download PDFInfo
- Publication number
- KR20140096771A KR20140096771A KR1020130009767A KR20130009767A KR20140096771A KR 20140096771 A KR20140096771 A KR 20140096771A KR 1020130009767 A KR1020130009767 A KR 1020130009767A KR 20130009767 A KR20130009767 A KR 20130009767A KR 20140096771 A KR20140096771 A KR 20140096771A
- Authority
- KR
- South Korea
- Prior art keywords
- platycodin
- pharmaceutical composition
- rti
- contact dermatitis
- preventing
- Prior art date
Links
- GWBIYORWNUYYMZ-UHFFFAOYSA-N platycodin D Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(O)C(O)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O GWBIYORWNUYYMZ-UHFFFAOYSA-N 0.000 title claims abstract description 49
- CYBWUNOAQPMRBA-NDTOZIJESA-N platycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CYBWUNOAQPMRBA-NDTOZIJESA-N 0.000 title claims abstract description 48
- 239000000284 extract Substances 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
- 229930189407 platycodin Natural products 0.000 title claims abstract 3
- 206010012442 Dermatitis contact Diseases 0.000 claims abstract description 55
- 208000010247 contact dermatitis Diseases 0.000 claims abstract description 48
- 238000002360 preparation method Methods 0.000 claims abstract description 28
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 208000003251 Pruritus Diseases 0.000 claims abstract description 9
- 230000007803 itching Effects 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims abstract description 5
- 241000332371 Abutilon x hybridum Species 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 235000013376 functional food Nutrition 0.000 claims description 18
- 230000036541 health Effects 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000006210 lotion Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 12
- 206010030113 Oedema Diseases 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 6
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000004088 foaming agent Substances 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 32
- 239000002537 cosmetic Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 7
- 201000004624 Dermatitis Diseases 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 3
- 235000013402 health food Nutrition 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- -1 Platycodin D compound Chemical class 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 22
- 235000014113 dietary fatty acids Nutrition 0.000 description 17
- 239000000194 fatty acid Substances 0.000 description 17
- 229930195729 fatty acid Natural products 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 208000002029 allergic contact dermatitis Diseases 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000000105 evaporative light scattering detection Methods 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000006748 scratching Methods 0.000 description 5
- 230000002393 scratching effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- COPFWAGBXIWZNK-UHFFFAOYSA-N 2,3-bis(6-methylheptanoyloxy)propyl 6-methylheptanoate Chemical compound CC(C)CCCCC(=O)OCC(OC(=O)CCCCC(C)C)COC(=O)CCCCC(C)C COPFWAGBXIWZNK-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 2
- 229960003338 crotamiton Drugs 0.000 description 2
- 229940031569 diisopropyl sebacate Drugs 0.000 description 2
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940100463 hexyl laurate Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003611 tocopherol derivatives Chemical class 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000013032 Hydrocarbon resin Substances 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000004840 adhesive resin Substances 0.000 description 1
- 229920006223 adhesive resin Polymers 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229920006270 hydrocarbon resin Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000010422 internal standard material Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 150000008130 triterpenoid saponins Chemical group 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물을 유효성분으로 포함하는 접촉성 피부염 예방 또는 치료용 약학적 조성물에 관한 것이다.
The present invention relates to a pharmaceutical composition for preventing or treating contact dermatitis comprising Platycodin D-containing Platycodin D as an active ingredient.
현대사회는 산업의 발달로 인한 환경오염과 합성물질의 생산 증가로 알레르기성 접촉성 피부염을 비롯한 피부질환의 발병빈도가 크게 증가하고 있다. 또한 도시인들은 생활환경이 서구화로 변화함에 따라 진드기, 습도 저하에 따라 증가하는 먼지, 애완견의 털, 꽃가루, 새로운 과일 및 음식 등 외부의 다양한 항원에 의한 알레르기 반응에 노출될 기회가 점차 커지고 있다. In the modern society, the incidence of skin diseases including allergic contact dermatitis is greatly increased due to the increase of environmental pollution and the production of synthetic materials due to the development of industry. In addition, urban people are increasingly exposed to allergic reactions caused by various external antigens, such as ticks, dusts that increase as humidity decreases, pet hair, pollen, new fruits and foods, as the living environment changes to westernization.
이러한 다양한 항원에 의한 알레르기 반응으로는 유아의 기관지 천식, 아토피성 피부염, 비염, 두드러기, 습진 등의 원인 중의 하나로 추정되는데 알레르기성 접촉성 피부염을 유발하는 항원 물질들은 점차 일상생활에서의 접촉 기회가 늘어나는 추세이다. Allergic reactions caused by these various antigens are considered to be one of the causes of infant asthma, atopic dermatitis, rhinitis, urticaria, eczema, etc. Antigens causing allergic contact dermatitis are increasingly encountered in everyday life Trend.
접촉성 피부염(contact dermatitis)은 외부 물질과의 접촉에 의하여 생기는 모든 피부염을 말하며, 접촉 물질 자체의 자극에 의하여 생기는 원발성 접촉성 피부염과 접촉물질에 대한 알레르기 반응이 있는 사람에게만 생기는 알레르기성 접촉성 피부염으로 구분된다.Contact dermatitis refers to all dermatitis caused by contact with external substances. It refers to allergic contact dermatitis, which occurs only in people with primary contact dermatitis caused by the stimulation of the contact substance itself and allergic reactions to contact substances. .
알레르기성 접촉성 피부염은 항원이 접촉된 국소부위에 발적, 구진, 소수포, 궤양 등의 증상을 나타내며, 알레르기성 항원의 감작과정과 동일항원의 재접촉에 의해 증상이 발현되는 지연형 과민반응에 속하는 면역질환이다. Allergic contact dermatitis is characterized by the appearance of redness, papules, small spots and ulcers on the localized areas where the antigen is contacted. It belongs to a delayed type hypersensitivity reaction in which symptoms are manifested by the sensitization process of allergic antigens and the re- It is an immune disease.
알레르기성 접촉성 피부염은 접촉된 항원이 랑게르한스(Langerhans) 세포에 전달된 후 항원의 고유과정을 거쳐 TH 세포 l(Helper T cell 1)에 전달되고 이 TH 세포가 분열하여 기억세포(memory cell)를 형성하게 되는 감작과정을 거친다. 이후 항원에 재감작되면 염증반응과 조직손상이 유발되어 증상이 발현하며 이러한 과정에서 IgE를 비롯한 많은 사이토카인(cytokine)이 방출된다.Allergic contact dermatitis after the contact antigen that is passed to the Langerhans (Langerhans) cells through a unique process, the antigen is delivered to the T H cells l (Helper T cell 1) to divide the the T H cell memory cells (memory cell ) To form a sensitizing process. When the antigen is re-sensitized, the inflammation reaction and tissue damage are induced to manifest symptoms, and many cytokines such as IgE are released during this process.
다시 말해, 접촉성 피부염은 후천적 면역반응에 의한 것으로 전에 접촉한 적이 있는 어떤 항원에 반응한 사람에게서 동일 물질에 다시 접촉이 되면 알레르기 반응으로, 특정 어떤 물질이 피부에 닿은 후 며칠이 지나 가려우면서 구진, 반점 등의 피부 증상이 나타나는 질환으로, 시간이 지나면서 피부에 나타난 증상을 말한다.
In other words, contact dermatitis is caused by an acquired immune response, which is an allergic reaction when the same substance is contacted again with a person who has previously been contacted with an antigen that has previously been contacted, , And spots. It refers to symptoms that appear on the skin over time.
도라지(Platycodon grandiflorum)는 초롱꽃과의 쌍떡잎식물로 여러해살이풀이며 높이는 1 m 정도이고, 털이 없고 뿌리는 비대하며 줄기는 1개 나거나 모여 나며 곧게 자란다. Platycodon grandiflorum ) is a dicotyledonous plant, a perennial plant, about 1 m high, has no hair, has large roots, and has one or more stems and grows straight.
꽃은 7∼8월에 하늘색 또는 흰색으로 피며, 종 모양의 꽃은 줄기 끝 또는 갈라진 가지 끝에 1송이가 달리며 꽃부리가 5개의 꽃잎으로 이루어진 통꽃이다. 꽃받침은 종 모양이며 5조각으로 갈라지고 각 조각은 삼각형 바소꼴(피침 모양)이며, 5개의 수술이 있고 암술머리는 5갈래로 갈라지며 하위 씨방이다.Flowers bloom in July or August in light blue or white, and bell-shaped flowers are a flower orchid with one petal on the tip of a stem or on the tip of a cracked branch and the flower corolla is made up of five petals. Calyxes are bell-shaped and are divided into 5 pieces. Each piece is triangular barcelial (lanceolate), and there are 5 stamens. The head of the stigma is divided into 5 branches and the lower ovary.
한방에서는 뿌리 또는 주피를 제거하여 만든 부분을 길경이라 하여 약재로 사용되고 산이나 들에 야생하며 한국·일본·중국 등지에 분포한다.In one room, the part made by removing roots or juniper is used as a medicinal material, and it is wild in mountains and fields and distributed in Korea, Japan, and China.
도라지의 주요 약리성분은 트리테르페노이드(triterpenoid)계 사포닌으로 밝혀졌으며 기관지분비를 항진시켜 가래를 삭히는 효능이 있으며, 도라지에서만 특별히 관찰되는 사포닌 성분은 진정, 해열, 진통, 진해, 거담, 혈당 강하, 콜레스테롤 대사개선, 항콜린, 항암작용 및 위산분비 억제효과 등 여러 약리효과가 있는 것으로도 알려져 있다.The main pharmacological component of the bellflower is triterpenoid saponin. It has the effect of eliminating the phlegm by increasing the bronchial secretion. The saponin component which is observed only in the bellflower is calm, fever, pain, calmness, , Improvement of cholesterol metabolism, anticholinergic, anticancer effect and inhibition of gastric acid secretion.
환경오염과 함께 점차적으로 증가하는 각종의 피부염 환자, 특히 접촉성 피부염 환자들에 대하여 장기간에 걸쳐 사용하여도 부작용이 적은 천연물로부터 알레르기반응을 완화시키면서 효과적으로 치료할 수 있는 치료제가 절실히 요구되고 있다.
There is a desperate need for a therapeutic agent capable of effectively alleviating the allergic reaction from natural products having a small side effect even if it is used for a long period of time for various dermatitis patients, especially contact dermatitis patients, which are gradually increasing together with environmental pollution.
이에, 본 발명자들은 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물이 접촉성 피부염의 가려움증 완화 및 염증치료 효과가 있음을 확인함으로써 본 발명을 완성하게 되었다.
Thus, the inventors of the present invention have completed the present invention by confirming that Platycodin D-containing Platycodin D is effective in relieving itching and treating inflammation of contact dermatitis.
본 발명의 목적은 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물을 유효성분으로 포함하는 접촉성 피부염 예방 또는 치료용 약학적 조성물을 제공하는데 있다. It is an object of the present invention to provide a pharmaceutical composition for preventing or treating contact dermatitis, which comprises a platycodin D-containing platycodone extract as an active ingredient.
본 발명의 다른 목적은 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물을 유효성분으로 포함하는 접촉성 피부염 예방 또는 치료용 피부외용제를 제공하는데 있다.It is another object of the present invention to provide an external preparation for skin for preventing or treating contact dermatitis, which comprises a platycodin D-containing platycodone extract as an active ingredient.
본 발명의 다른 목적은 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물을 유효성분으로 포함하는 접촉성 피부염 개선 또는 완화용 건강기능식품을 제공하는데 있다.
Another object of the present invention is to provide a health functional food for improving or alleviating contact dermatitis comprising Platycodin D-containing Platycodon D as an active ingredient.
상기 목적을 달성하기 위해, 본 발명은 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물로서, 가려움증을 완화시키고 외부물질과 접촉에 의해여 생기는 피부염에 효과를 나타내는, 약학적 조성물, 피부 외용제 및 건강기능식품으로 사용할 수 있다.
In order to achieve the above object, the present invention provides a bellflower extract containing Platycodin D, which is a pharmaceutical composition, an external preparation for skin and a composition for external application, which shows effects on dermatitis caused by contact with external substances, It can be used as a health functional food.
상기 목적을 달성하기 위해, 본 발명은 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물로서, 가려움증을 완화시키고 외부물질과 접촉에 의해여 생기는 피부염에 효과를 나타내는, 약학적 조성물, 피부 외용제 및 건강기능식품으로 사용할 수 있다.
In order to achieve the above object, the present invention provides a bellflower extract containing Platycodin D, which is a pharmaceutical composition, an external preparation for skin and a composition for external application, which shows effects on dermatitis caused by contact with external substances, It can be used as a health functional food.
도 1은 DNCB로 접촉성 피부염이 유도된 마우스의 등쪽 표피에 플라티코딘 D(Platycodin D) 함유 도라지 추출물을 도포한 후의 긁는 행위의 변화를 확인하여 나타낸 그래프이다.
도 2은 DNCB로 접촉성 피부염이 유도된 마우스의 등쪽 표피에 플라티코딘 D(Platycodin D) 함유 도라지 추출물을 도포한 후의 피부 관능 평가를 확인하여 나타낸 그래프이다.
도 3은 DNCB로 접촉성 피부염이 유도된 마우스의 등쪽 표피에 플라티코딘 D(Platycodin D) 함유 도라지 추출물을 도포한 후의 등쪽 표피를 조직 적출한 뒤 헤마톡실린 및 에오신 염색 과정을 거친 뒤 현미경 관찰하여 촬영한 사진이다.(각 각 40배 확대, 100배 확대한 현미경 관찰 사진에 관한 것이다.)FIG. 1 is a graph showing changes in scratching behavior after application of platycodin D-containing bellflower extract to the dorsal skin of mice in which contact dermatitis was induced by DNCB.
FIG. 2 is a graph showing skin sensory evaluation after application of platycodin D-containing bellflower extract to the dorsal skin of mice in which contact dermatitis was induced by DNCB.
FIG. 3 shows the results of tissue extractions of the dorsal epidermis after platycodin D-containing bellflower extract was applied to the dorsal skin of the dorsal skin of contact dermatitis induced by DNCB, followed by hematoxylin and eosin staining, (It relates to a microscope observation image enlarged by a factor of 40 and magnified by a factor of 100, respectively.)
하기 화학식 1로 표시되는 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물을 유효성분으로 포함하는 접촉성 피부염 예방 또는 치료용 약학적 조성물을 제공하는 것을 그 특징으로 한다:The present invention provides a pharmaceutical composition for preventing or treating contact dermatitis, which comprises, as an active ingredient, a bellflower extract containing Platycodin D represented by the following formula (1):
[화학식 1][Chemical Formula 1]
본 발명의 일 실시양태에서, 플라티코딘 D(Platycodin D) 화합물은 플라바논(flavanone)의 한 종류로 IUPAC 명칭은 3β-(β-D-glucopyranosyloxy)-2β,16α,23,24-tetrahydroxy-O-D-apio-β-D-furanosyl-(1→3)-O-β-D-xylopyranosyl-(1→4)-O-6-deoxy-olean-12-en-28-oic acid이며, 이 물질의 분자식(Molecular Formula)은 C57H92O28이고, 분자량(Molecular Weight)은 1225.32 이다. In one embodiment of the present invention, the Platycodin D compound is a kind of flavanone, and the IUPAC designation is 3? - (? - D-glucopyranosyloxy) -2 ?, 16 ?, 23,24-tetrahydroxy- OD-apio-β-D-furanosyl- (1 → 3) -O- β-D-xylopyranosyl- (1 → 4) -O-6-deoxy-olean-12-en-28- The molecular formula (Molecular Formula) is C 57 H 92 O 28 , and the molecular weight (Molecular Weight) is 1225.32.
본 발명의 플라티코딘 D 화합물을 천연물로부터 분리되거나 또는 당업계에 공지된 화학적 합성법으로 제조하여 사용할 수 있으며, 시중에서 판매되고 있는 플라티코딘 D 화합물을 상업적으로 입수하여 사용할 수도 있다.The platycodine D compound of the present invention can be isolated from natural products or can be prepared by a chemical synthesis method known in the art, and commercially available platycodine D compounds can be commercially obtained and used.
본 발명에 따른 일 실시양태에서, 상기 약학적 조성물은 가려움증을 완화하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물에 관한 것이다.In one embodiment according to the present invention, the pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of contact dermatitis characterized by relieving itching.
본 발명에 따른 일 실시양태에서, 상기 약학적 조성물은 염증반응을 억제하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물에 관한 것이다.In one embodiment according to the present invention, the pharmaceutical composition is a pharmaceutical composition for preventing or treating contact dermatitis characterized by inhibiting an inflammatory reaction.
본 발명에 따른 일 실시양태에서, 상기 약학적 조성물은 부종을 억제하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물에 관한 것이다. In one embodiment according to the present invention, the pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of contact dermatitis characterized by inhibiting edema.
본 발명에 따른 일 실시양태에서, 상기 접촉성 피부염은 외부물질과의 접촉에 의한 접촉성 피부염인 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물에 관한 것이다.In one embodiment according to the present invention, the contact dermatitis is a contact dermatitis caused by contact with an external substance, and a pharmaceutical composition for preventing or treating contact dermatitis.
또한, 본 발명의 약학적 조성물은 천연물 추출물 또는 이로부터 분리된 성분을 유효성분으로 하기 때문에 거의 독성을 가지지 않으며, 인체에 무해하다.
In addition, the pharmaceutical composition of the present invention has almost no toxicity because it is a natural product extract or a component isolated therefrom as an active ingredient, and is harmless to the human body.
본 발명의 일 실시양태에서, 상기 약학적 조성물 중 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물 파우더는 전체 약학적 조성물 중량의 0.0001 내지 0.1 중량%인 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물에 관한 것이다.In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the pharmaceutical composition is 0.0001 to 0.1% by weight of the total pharmaceutical composition. ≪ / RTI >
본 발명의 일 실시양태에서, 플라티코딘 D(Platycodin D) 함유 도라지 추출물은 도라지를 물 또는 탄소수 1 내지 4의 저급 알코올로 추출하고 발효시킨 후 원심분리하여 고형분을 제거한 후, 농축, 동결건조 과정을 거쳐 제조된 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물에 관한 것이다.In one embodiment of the present invention, Platycodin D-containing bellflower extract is prepared by extracting bellflower with water or a lower alcohol having 1 to 4 carbon atoms, fermenting it, centrifuging it to remove solid content, concentrating, The present invention also relates to a pharmaceutical composition for preventing or treating contact dermatitis.
본 발명의 일 실시양태에서, 도라지(Platycodon grandiflorum)를 물 또는 탄소수 1내지 4의 저급 알코올로 추출하고 발효시킨 후, 원심분리하여 고형분을 제거하는 단계; 농축, 동결건조 시키는 단계를 포함하는 접촉성 피부염 예방 또는 치료용 플라티코딘 D 함유 도라지 추출물을 제조하는 방법을 제공하는 것을 그 특징으로 한다.
In one embodiment of the invention, bellflower (Platycodon grandiflorum ) is extracted with water or a lower alcohol having 1 to 4 carbon atoms, fermented, and centrifuged to remove solid matter; Concentrating and freeze-drying a platycodin D-containing bellflower extract for preventing or treating contact dermatitis.
본 발명의 일 실시양태에서, 하기 화학식 1로 표시되는 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물을 접촉성 피부염 예방 또는 치료용 피부외용제를 제공하는 것을 그 특징으로 한다:In one embodiment of the present invention, a Platycodin D-containing Platycodin D represented by the following Formula 1 is characterized by providing an external preparation for skin for preventing or treating contact dermatitis:
[화학식 1][Chemical Formula 1]
본 발명의 일 실시양태에서, 상기 약학적 조성물은 려움증을 완화하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 피부외용제에 관한 것이다.In one embodiment of the present invention, the pharmaceutical composition relates to an external preparation for skin for prevention or treatment of contact dermatitis characterized by relieving itching.
본 발명의 일 실시양태에서, 상기 약학적 조성물은 염증반응을 억제하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 피부외용제에 관한 것이다. In one embodiment of the present invention, the pharmaceutical composition is an external preparation for skin for preventing or treating contact dermatitis characterized by inhibiting an inflammatory reaction.
본 발명의 일 실시양태에서, 상기 약학적 조성물은 부종을 억제하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 피부외용제에 관한 것이다.In one embodiment of the present invention, the pharmaceutical composition is an external preparation for skin for preventing or treating contact dermatitis characterized by inhibiting edema.
본 발명의 일 실시양태에서, 상기 피부외용제는 연고제, 크림제, 로숀제, 액제, 드레싱제, 패취제, 수포제, 테이프제, 연무제, 외용산제 및 스프레이제로 이루어진 그룹으로부터 선택되는 어느 하나로 제형화 될 수 있다.In one embodiment of the present invention, the external preparation for skin is formulated into any one selected from the group consisting of ointments, creams, lotions, liquids, dressings, patches, foams, tapes, aerosols, external powders and spraying agents .
본 발명의 플라티코딘 D 함유 도라지 추출물을 함유한 피부외용제는 연고제, 용액제(예를 들면 현탁액, 유화액, 로션), 수포제, 테이프제, 연무제 및 외용산제와 같은 피부의 국부적 표면에 직접 적용될 수 있는 한 제한되지 않는다. 플라티코딘 D 함유 도라지 추출물의 양은 제제에 따라 다르지만, 연고제, 크림제, 겔제와 로션제의 경우, 예를 들면 0.001 내지 0.1w/v%, 수포제의 경우 0.001 내지 0.2w/v%, 테이프제의 경우 0.001 내지 0.2w/v%, 및 외용산제의 경우 0.001 내지 0.2w/v%일 수 있다.
The external preparation for skin containing the platycodine D-containing bellows extract of the present invention can be applied directly to the local surface of the skin such as an ointment, a solution (e.g., suspension, emulsion, lotion), a foaming agent, a tape agent, So long as it can be applied. The amount of the platycodin D-containing bellflower extract varies depending on the preparation. For example, it is 0.001 to 0.1 w / v% for ointments, creams, gels and lotions, 0.001 to 0.2 w / 0.001 to 0.2 w / v% in the case of the external preparation and 0.001 to 0.2 w / v% in the external preparation.
본 발명의 일 실시양태에서, 상기 약학적 조성물 중 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물 파우더는 전체 약학적 조성물 중량의 0.0001 내지 0.1 중량%인 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 피부외용제에 관한 것이다.
In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the pharmaceutical composition is 0.0001 to 0.1% by weight of the total pharmaceutical composition. Skin external preparation for skin.
본 발명의 일 실시양태에서, 하기 화학식 1로 표시되는 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물 접촉성 피부염 개선 또는 완화용 화장료 조성물을 제공하는 것을 그 특징으로 한다:In one embodiment of the present invention, there is provided a cosmetic composition for improving or alleviating contact dermatitis comprising Platycodin D represented by the following formula (1):
[화학식 1][Chemical Formula 1]
본 발명의 제제의 활성성분 이외의 다른 성분들은 일반적으로 외용제에 사용되는 어떠한 성분이 사용될 수 있다. 연고제, 크림제, 겔제 및 로션제의 경우, 백색와셀린(와셀린), 황색와셀린, 라놀린, 정제 밀랍, 세타놀, 스테아릴 알콜, 스테아르산, 수소첨가유, 탄화수소겔, 폴리에틸렌 글리콜, 액체 파라핀 및 스쿠알란과 같은 기제; 올레산, 이소프로필 미리스테이트, 글리세롤 트리이소옥타노에이트, 크로타미톤, 디에틸 세바케이트, 디이소프로필 세바케이트, 디이소프로필아디페이트, 헥실라울레이트, 지방산, 지방산 에스테르, 식물성유, 지방산 알콜 및 알콜과 같은 용매 또는 안정화제; 토코페롤 유도체, L-아스코르브산, 디부틸히드록시톨루엔 및 부틸히드록시아니졸과 같은 항산화제; p-히드록시벤조에이트와 같은 방부제; 글리세린, 프로필렌 글리콜 및 소듐히알루로네이트와 같은 연석제; 폴리옥시에틸렌 유도체, 글리세롤 지방산 에스테르, 수크로스 지방산 에스테르, 소르비탄 지방산 에스테르, 프로필렌 글리콜 지방산 에스테르 및 레시틴과 같은 계면활성제; 카르복시비닐 폴리머, 크산검, 카르복시메틸 셀룰로스 및 소듐 카르복시메틸 셀룰로스, 히드록시프로필 셀룰로스 및 히드록시프로필메틸 셀룰로스와 같은 증점제; 안정화제; 보존제; 흡착 촉진제; 및 기타 적당한 충진제들이 첨가될 수 있다.Other ingredients than the active ingredient of the formulation of the present invention may be any ingredient commonly used in external preparations. In the case of ointments, creams, gels and lotions, there may be used white petrolatum (vaseline), yellow petrolatum, lanolin, purified beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane A mechanism such as; Oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamitone, diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, hexyllaurate, fatty acid, fatty acid ester, vegetable oil, Solvents or stabilizers such as alcohols; Tocopherol derivatives, antioxidants such as L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; preservatives such as p-hydroxybenzoate; Curling agents such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and lecithin; Thickeners such as carboxyvinyl polymer, xanthan gum, carboxymethylcellulose and sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Stabilizers; Preservatives; Adsorption promoters; And other suitable fillers may be added.
수포제의 경우, 폴리아크릴산과 폴리아크릴산 공중합체와 같은 점착제; 알루미늄설페이트, 알루미늄 포타슘 설페이트, 알루미늄 클로라이드, 마그네슘 알루미노메타실리케이트 및 디히드록시알루미늄 아미노아세테이트와 같은 가교제; 소듐 폴리아크릴레이트, 폴리비닐알콜, 폴리비닐피롤리돈, 젤라틴, 소듐알기네이트, 카르복시메틸 셀룰로스, 소듐 카르복 시메틸 셀룰로스, 히드록시프로필 셀룰로스와 히드록시프로필메틸 셀룰로스와 같은 증점제; 글리세린, 폴리에틸렌글리콜 (마크로골), 폴리에틸렌글리콜과 1,3-부탄디올과 같은 다가알콜; 폴리옥시에틸렌 유도체와 같은 계면활성제; ℓ-멘톨과 같은 향료; p-히드록시벤조에이트와 같은 방부제; 정제수; 및 기타 적당한 충진제가 첨가될 수 있다.In the case of the blowing agent, an adhesive such as a polyacrylic acid and a polyacrylic acid copolymer; A crosslinking agent such as aluminum sulfate, aluminum potassium sulfate, aluminum chloride, magnesium aluminometasilicate and dihydroxy aluminum aminoacetate; Thickening agents such as sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, sodium alginate, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Polyhydric alcohols such as glycerin, polyethylene glycol (macrogol), polyethylene glycol and 1,3-butanediol; Surfactants such as polyoxyethylene derivatives; fragrances such as l-menthol; preservatives such as p-hydroxybenzoate; Purified water; And other suitable fillers may be added.
테이프제의 경우, 스틸렌-이소프렌-스틸렌 블럭 공중합체 및 아크릴레이트 수지와 같은 점착제; 아크릴성 포화탄화수소 수지, 수소 첨가된 로신 수지 및 테르펜 수지와 같은 점착 수지; 액체 검과 액체 파라핀과 같은 유연제; 디부틸히드록시톨루엔과 같은 항산화제; 폴리에틸렌글리콜과 같은 다가알콜; 올레산과 같은 흡착 촉진제; 폴리옥시에틸렌 유도체와 같은 계면활성제; 및 기타 적당한 충진제가 첨가될 수 있다. 그밖에, 소듐 폴리아크릴레이트와 폴리비닐알콜과 같은 물흡수성 폴리머와 소량의 정제수가 물을 함유하는 테이프제의 제조에 첨가될 수 있다.In the case of a tape, a pressure-sensitive adhesive such as a styrene-isoprene-styrene block copolymer and an acrylate resin; Adhesive resins such as acrylic saturated hydrocarbon resins, hydrogenated rosin resins and terpene resins; Softeners such as liquid gums and liquid paraffin; Antioxidants such as dibutylhydroxytoluene; Polyhydric alcohols such as polyethylene glycol; Adsorption promoters such as oleic acid; Surfactants such as polyoxyethylene derivatives; And other suitable fillers may be added. In addition, water-absorbing polymers such as sodium polyacrylate and polyvinyl alcohol and a small amount of purified water can be added to the preparation of tapes containing water.
연무제의 경우, 백색와셀린(와셀린), 황색와셀린, 라놀린, 정제 밀랍, 세타놀, 스테아릴 알콜, 스테아르산, 수소첨가유, 탄화수소겔, 폴리 에틸렌글리콜, 액체 파라핀 및 스쿠알란과 같은 기제; 올레산, 이소프로필 미리스테이트, 글리세롤 트리이소옥타노에이트, 크로타미톤, 디에틸세바케이트, 디이소프로필 세바케이트, 이소프로필 아디페이트, 헥실 라우레이트, 지방산, 지방산 에스테르, 식물성유, 지방족 알콜 및 알콜과 같은 용매 또는 안정화제; 토코페롤 유도체, L-아스코르브산, 디부틸히드록시톨루엔 및 부틸히드록시아니졸과 같은 항산화제; p-히드록시벤조에이트와 같은 방부제; 글리세린, 프로필렌 글리콜 및 소듐히알루로네이트와 같은 연석제; 폴리옥시에틸렌 유도체, 글리세롤 지방산 에스테르, 수크로스 지방산 에스테르, 소르비탄 지방산 에스테르, 프로필렌글리콜 지방산 에스테르 및 레시틴과 같은 계면 활성제 연고, 크림, 겔 또는 로션에 사용되는 것과 같은 카르복시비닐 폴리머, 크산검, 카르복시메틸 셀룰로스 및 소듐 카르복시메틸 셀룰로스, 히드록시프로필 셀룰로스 및 히드록시프로필메틸 셀룰로스와 같은 증점제; 안정화제; 완충제; 감미제 현탁제; 유화제; 조미료; 방부제; 흡착 촉진제 및 기타 적당한 충진제들이 첨가될 수 있다.In the case of an aerosol agent, bases such as white petrolatum (Vaseline), yellow petrolatum, lanolin, purified beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane; Oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamitone, diethyl sebacate, diisopropyl sebacate, isopropyl adipate, hexyl laurate, fatty acid, fatty acid ester, vegetable oil, aliphatic alcohol and alcohol A solvent or a stabilizer such as; Tocopherol derivatives, antioxidants such as L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; preservatives such as p-hydroxybenzoate; Curling agents such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and lecithin, carboxyvinyl polymers such as those used in creams, gels or lotions, xanthan gum, carboxymethyl Thickeners such as cellulose and sodium carboxymethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose; Stabilizers; Buffering agents; Sweetener suspension; Emulsifiers; Condiment; antiseptic; Adsorption promoters and other suitable fillers may be added.
외용산제의 경우, 감자전분, 쌀전분, 옥수수 전분, 탈크 및 산화아연과 같은 충진제, 및 기타 적당한 첨가제들이 첨가될 수 있다.For external powders, potato starch, rice starch, corn starch, fillers such as talc and zinc oxide, and other suitable additives may be added.
본 발명의 피부외용제는 외용제를 제조하는데 잘 알려진 방법에 따라, 필요에 따라 적당한 기제와 함께, 각 성분을 잘 혼합하여 제조될 수 있으며 이와 같이 제조된 제제는 필요에 따라 병변에 적용된다.The external preparation for skin of the present invention may be prepared by mixing well-known ingredients with appropriate bases according to a well-known method for preparing external preparations, and the thus-prepared preparation is applied to lesions as required.
본 발명의 일 실시양태에서, 상기 화장료 조성물은 가려움증을 완화하는 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 화장료 조성물에 관한 것이다.In one embodiment of the present invention, the cosmetic composition is characterized in that it alleviates itching. The present invention relates to a cosmetic composition for improving or alleviating contact dermatitis.
본 발명의 일 실시양태에서, 상기 화장료 조성물은 염증반응을 완화하는 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 화장료 조성물에 관한 것이다.In one embodiment of the present invention, the cosmetic composition is a cosmetic composition for improving or alleviating contact dermatitis characterized by alleviating an inflammatory reaction.
본 발명의 일 실시양태에서, 상기 화장료 조성물은 부종을 완화하는 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 화장료 조성물에 관한 것이다.In one embodiment of the present invention, the cosmetic composition is a cosmetic composition for improving or alleviating contact dermatitis characterized by alleviating edema.
또한, 본 발명의 플라티코딘 D 함유 도라지 추출물을 이용한 조성물에는 생약제제 등과 같은 기능성 물질을 포함시켜 조성물의 향을 개선시키거나 접촉성 피부염 개선 효과를 높일 수 있다.
In addition, the composition using the platycodine D-containing bellows extract of the present invention may contain a functional substance such as a herbal preparation to improve the fragrance of the composition or improve the contact dermatitis improving effect.
본 발명의 일 실시양태에서, 상기 화장료 조성물 중 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물 파우더는 전체 화장료 조성물 중량의 0.00001 내지 1중량%인 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 화장료 조성물에 관한 것이다.In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the cosmetic composition is 0.00001 to 1 wt% of the total weight of the cosmetic composition. The cosmetic composition for improving or alleviating contact dermatitis ≪ / RTI >
본 발명의 일 실시양태에서, 상기 화장료 조성물 중 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물 파우더는 전체 화장료 조성물 중량의 0.0001 내지 0.1중량%인 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 화장료 조성물에 관한 것이다.In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the cosmetic composition is 0.0001 to 0.1% by weight of the total weight of the cosmetic composition. The cosmetic composition for improving or alleviating contact dermatitis ≪ / RTI >
본 발명의 일 실시양태에서, 상기 화장료 조성물 중 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물 파우더는 전체 화장료 조성물 중량의 0.001 내지 0.01중량%인 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 화장료 조성물에 관한 것이다.In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the cosmetic composition is 0.001 to 0.01 wt% of the total weight of the cosmetic composition. The cosmetic composition for improving or alleviating contact dermatitis ≪ / RTI >
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 종래의 화장료제형인 피부외용연고, 에센스, 미백크림, 로션, 에멀젼, 팩, 일반화장수, 스킨밀크, 크림, 세럼, 미용비누, 유연화장수, 약용화장수, 헤어토닉, 전신세정제, 오일젤과 같은 여러 가지 형태로 제조할 수 있다.The cosmetic composition of the present invention can be prepared in any formulations conventionally produced in the art and can be used in cosmetic formulations such as external ointments for skin, essence, whitening cream, lotion, emulsion, pack, general lotion, Serum, cosmetic soap, softening lotion, medicated lotion, hair tonic, whole body cleanser, oil gel and the like.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
본 발명의 일 실시양태에서, 하기 화학식 1로 표시되는 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물을 유효성분으로 함유하는 접촉성 피부염 개선 또는 완화용 건강기능식품을 제공하는 것을 그 특징으로 한다:In one embodiment of the present invention, there is provided a health functional food for improving or alleviating contact dermatitis, which comprises, as an active ingredient, a Platycodin D-containing platycodin D represented by the following formula (1) do:
[화학식 1][Chemical Formula 1]
본 발명의 일 실시양태에서, 상기 건강기능식품은 가려움증을 완화하는 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 건강기능식품.In one embodiment of the present invention, the health functional food is a health functional food for improving or alleviating contact dermatitis, which alleviates itching.
본 발명의 일 실시양태에서, 상기 건강기능식품은 염증반응을 완화하는 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 건강기능식품.In one embodiment of the present invention, the health functional food is a health functional food for improving or alleviating contact dermatitis, which alleviates an inflammatory reaction.
본 발명의 일 실시양태에서, 상기 건강기능식품은 부종을 완화하는 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 건강기능식품.In one embodiment of the present invention, the health functional food is a health functional food for alleviating edema.
본 발명의 일 실시양태에서, 상기 건강기능식품 중 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물 파우더는 전체 건강기능식품 중량의 0.001 내지 1중량%인 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 건강기능식품.
In one embodiment of the present invention, the bellflower extract powder containing Platycodin D in the health functional food is 0.001 to 1 wt% of the total weight of the health functional food. Health functional food for.
이하, 하기 실험예 및 제조예를 통하여 본 발명에 대하여 보다 상세히 설명하고자 한다. 다만 이는 본 발명에 대한 이해를 돕기 위한 것이지, 본 발명의 권리범위를 이로 한정하려는 의도는 아니다.
Hereinafter, the present invention will be described in more detail with reference to the following Experimental Examples and Preparation Examples. It should be understood, however, that the same is by way of illustration and example only and is not intended to limit the scope of the present invention.
[실시예 1] 플라티코딘 D 함유 도라지 추출물의 제조방법 [Example 1] Method for producing platycodin D-containing bellflower extract
표준화된 1 중량%, 3 중량%, 5 중량% 플라티코딘 D 함유 도라지 추출물은 (주)비엔씨바이오팜으로부터 공급받았으며, 구체적인 제조는 다음과 같다. Standardized 1% by weight, 3% by weight, 5% by weight platycodin D-containing bellflower extract was supplied from BN C Co., Ltd., and specific preparation was as follows.
도라지 원료를 물(정제수), 에탄올 또는 메탄올을 이용하여 2회 이상 추출하고 여기서 얻어진 추출물을 발효 후 원심분리하여 고형분을 제거한 다음 농축하고 동결건조하여 용매가 제거된 각각의 추출물을 확보하였다. 추출물로부터 단일 활성성분을 분리정제하기 위하여 위에서 얻어진 추출물을 물로 완전히 녹인 다음 RP-18, Diaion HP-20, 그리고 이온 교환 겔 컬럼(Ion exchange gel column)을 이용하여 각 분획 별 활성을 확인한 후 활성을 보이는 분획만을 얻어내었고, 추가 HPLC 과정을 통해 각 단일 활성성분을 분리 정제하였다. The raw material of the bellflower was extracted more than twice with water (purified water), ethanol or methanol, and the obtained extract was centrifuged after fermentation to remove solid components, followed by concentration and lyophilization to obtain respective extracts from which the solvent was removed. In order to separate and purify the single active component from the extract, the extract obtained above was completely dissolved in water, and the activity of each fraction was confirmed using RP-18, Diaion HP-20, and ion exchange gel column Only the visible fractions were obtained, and each single active component was isolated and purified by further HPLC.
○ 분석기기○ Analysis equipment
- HPLC system : Agilent 1260 series- HPLC system: Agilent 1260 series
- Column : Kinetex C18 column (2.6 ㎛, 4.6 mm x 100 mm, Phenomenex, Germany)Column: Kinetex C 18 column (2.6 탆, 4.6 mm x 100 mm, Phenomenex, Germany)
- 검출기 : Alltech ELSD 2000
- Detector: Alltech ELSD 2000
○ HPLC 및 ELSD 조건○ HPLC and ELSD conditions
시료는 Agilent 1260 series HPLC를 이용하여 분석하였다. Samples were analyzed using Agilent 1260 series HPLC.
컬럼은 C18 column(2.6 ㎛, 4.6 mm x 100 mm, Phenomenex, Germany)을 사용하였으며, 이동상은 0.15% 포름산(A), 아세토니트릴(B), 메탄올(C)를 사용하였고, 다음과 같은 조건으로 기울기 용매흘림(gradient flow) 방법으로 대상물질인 플라티코딘 D를 분석하였다. The mobile phase used was 0.15% formic acid (A), acetonitrile (B), and methanol (C), and the following conditions were used for the column: C 18 column (2.6 ㎛, 4.6 mm x 100 mm, Phenomenex, Germany) And the platycodine D, which is a target substance, was analyzed by a gradient flow method.
기울기 용매흘림 완료 후 컬럼의 안정화를 위해 10분간 0.15% 포름산(A) : 아세토니트릴(B) : 메탄올(C) = 75 : 20 : 5 (v/v) 로 post-run을 실시하였다. 이때, 시료의 주입량 및 유속은 20 ㎕ 와 0.6 ml/min 로 조정하였다.After completion of the slurry solvent elution, post-run was performed with 0.15% formic acid (A): acetonitrile (B): methanol (C) = 75: 20: 5 (v / v) for 10 minutes to stabilize the column. At this time, the injection amount and the flow rate of the sample were adjusted to 20 μl and 0.6 ml / min.
플라티코딘 D 시료의 검출은 ELSD 검출기를 이용하였으며, 이때 건조가스는 질소를 사용하였으며 유속 및 온도는 1.5 L/min 및 80℃로 설정하여 플라티코딘 D를 정량하였다.
Platycodin D samples were detected by ELSD detector. Platycodin D was quantified by setting the flow rate and temperature at 1.5 L / min and 80 ° C using nitrogen as the drying gas.
○ 플라티코딘 D 표준품의 표준정량곡선○ Standard quantitative curve of platycodine D standard
플라티코딘 D는 상용 표준품(Futoro lab.사)을 정확히 계량하여 50% 메탄올에 용해시킨 다음 HPLC/ELSD를 이용, 표준정량곡선을 그려 플라티코딘 D 함량을 확인하였다. 플라티코딘 D 상용 표준품으로부터 구한 표준정량곡선의 검량선 계산식은 y=17.757x-643.76 (R2=0.999)로 양호한 직선성을 나타내었다. Platycodin D was accurately weighed and dissolved in 50% methanol, and then platycodin D content was determined using a standard quantitative curve using HPLC / ELSD. Calibration curve of the standard quantitative curve obtained from the standard product of platycodine D showed good linearity at y = 17.757x-643.76 (R 2 = 0.999).
시험물질의 표준화를 위하여 각 시료를 50% 메탄올에 20 mg/ml이 되도록 용해한 다음 불순물을 제거하고 (0.45 ㎛ filter) HPLC/ELSD 검출을 실시하였다. For standardization of the test materials, each sample was dissolved in 50% methanol to a concentration of 20 mg / ml, and impurities were removed (0.45 μm filter) and HPLC / ELSD detection was performed.
얻어진 크로마토그램으로부터 내부 표준물질의 피크 면적에 대한 플라티코딘 D 의 피크 면적비를 구하여 미리 작성한 표준곡선으로부터 추출물 내의 플라티코딘 D 농도를 구하여 제품을 표준화하였다.
From the chromatogram obtained, the peak area ratio of platidone D to the peak area of the internal standard material was determined, and the concentration of platycodin D in the extract was determined from a previously prepared standard curve to normalize the product.
[실험예 1] 알레르기성 접촉성 피부염 유도 (실험동물의 준비)[Experimental Example 1] Induction of allergic contact dermatitis (preparation of experimental animals)
알레르기성 접촉성 피부염 유도하기 위해 지연형 과민반응의 항원으로 DNCB(2,4-dinitrochlorobenzene)를 아세톤과 올리브오일의 혼합용액(혼합 부피 비율 3:1)에 1%가 되게 용해한 후 7주령의 수컷 ICR 마우스의 등쪽 부위 2 ㎝2에 300 ㎕를 도포하여 1차 면역시켰다. 1차 면역 4일 경화 후 0.5% DNCB를 등쪽 부위에 250 ㎕ 도포하고 이를 약 2주간 지속적으로 동일 농도, 동일 양을 처리해 줌으로써 2차 면역을 실시하였다. 플라티코딘 D 함유 도라지 추출물을 도포하는 군은 2차 DNCB 투여 시부터 격일 단위로 한번씩 0.2 mg/mℓ의 농도로 등쪽 부위에 200 ㎕씩을 도포하였다.
To induce allergic contact dermatitis, DNCB (2,4-dinitrochlorobenzene) was dissolved in a mixed solution of acetone and olive oil (mixing volume ratio 3: 1) to 1% as an antigen of delayed hypersensitivity reaction. 300 [mu] L of the ICR mouse was applied to 2 cm 2 of the dorsal area, and the mice were first immunized. Primary immunization After 4 days of curing, 250 μl of 0.5% DNCB was applied to the dorsal area and the second immunization was performed by treating the same amount and the same amount continuously for about 2 weeks. Platycodin D-containing bellflower extracts were applied at a dose of 0.2 mg / ml once every other day, 200 μl / well to the back of the second DNCB administration.
[실험예 2] 긁는 행위의 변화[Experimental Example 2] Changes in scratching behavior
2차 항원투여 후 24시간 간격으로 동영상 촬영을 통해 접촉성 피부염에 의해 발생되는 긁는 행위의 횟수를 측정 할 수 있는 긁는 행위 확인 실험을 실시하였다. DNCB의 2차 도포 후 등쪽 표피의 부족이 지속적으로 발생한 뒤로 개체의 등쪽 부위를 긁는 행위는 계속해서 증가하는 양상을 확인하였다. After the second antigen administration, video recording was performed at 24-hour intervals to check the degree of scratching caused by contact dermatitis. After the secondary application of DNCB, the back of the dorsal epidermis continued to develop, and scratching of the dorsal part of the subject continued to increase.
플라티코딘 D 함유 도라지 추출물을 함께 투여한 군에서는 3번째 투여 이후에는 점차 긁는 행위가 감소되어 회복되는 것을 관찰할 수 있었다(도 1).
In the group administered with platycodin D-containing bellflower extract, it was observed that after the third administration, the scratching was gradually reduced and recovered (FIG. 1).
[실험예 3] 피부 관능 평가 실시[Experimental Example 3] Skin sensory evaluation was carried out
피부 상태를 홍반, 가려움과 건조피부, 부종과 혈종, 짓무름, 태선화, 이 5항목에 대해 증상없음 0점, 증상 약함 1점, 보통 2점, 심함 3점으로 채점한 후, 5항목의 점수를 합산함으로써 최소 0점(아무 증상이 없는 상태)에서 최고 15점(모든 항목의 증상이 심한 상태)사이의 평가 점수를 부여하였다. After scoring 0 points for symptom free, 1 point for symptom weakness, 2 points for normal symptom, 3 points for severe symptom for these 5 items, score 5 items The sum of the scores gave a score of at least 0 (no symptoms) to a maximum of 15 (all symptoms were severe).
이를 통한 피부 관능평가에서 DNCB를 도포하여 접촉성 피부염이 유발된 군에서는 점수가 점차 증가하여 13점 이상에 이르렀으나, 플라티코딘 D 함유 도라지 추출물을 함께 도포한 실험군에서는 정상군의 수준만큼 현저히 저하되는 것을 확인할 수 있었다(도 2).
In the skin sensory evaluation, DNCB was applied in the contact dermatitis - induced group, the score increased gradually to over 13 points, but in the group treated with platycodine D - containing bellflower extract, (Fig. 2).
[실험예 4] 등쪽 표피의 두께의 변화(등쪽 표피 부종 확인)[Experimental Example 4] Changes in the thickness of dorsal epidermis (confirmed dorsal epidermal edema)
등쪽 표피의 두께는 등쪽 표피를 조직 적출 한 후에 헤마톡실린 및 에오신 염색을 실시하여 확인하였다. 정상군에 비하여 DNCB의 2차 도포 후 등쪽 표피의 부종이 지속적으로 발생하여 두께가 증가되었다. The dorsal epidermal thickness was determined by hematoxylin and eosin staining after dorsal epidermal tissue extraction. After the second application of DNCB, edema of the dorsal epidermis continuously occurred and the thickness was increased.
플라티코딘 D 함유 도라지 추출물을 투여한 군에서는 3번째 투여부터 유의하게 부종이 완화되었고 상기 결과로 인해 플라티코딘 D 함유 도라지 추출물에 항염증효과가 있다는 것으로 관찰되었다(도 3).
In the group treated with platycodin D-containing bellflower extract, edema was significantly alleviated from the third administration, and as a result, it was observed that the platycodin D-containing bellflower extract had an anti-inflammatory effect (FIG. 3).
상기 성분들을 분말화하여 혼합한 후 기밀포에 충진하여 산제를 제조한다.
The above components are powdered and mixed, and filled in an airtight container to prepare a powder.
통상의 정제의 제조방법에 따라 상기 성분들을 혼합한 후 이를 타정하여 정제를 제조한다.
The tablets are prepared by mixing the above components according to a conventional method for producing tablets and then tableting them.
통상의 캅셀제의 제조방법에 따라 상기 성분들을 혼합한 후 젤라틴 캡슐에 충진하여 캅셀제를 제조한다.
The above components are mixed according to a conventional method for preparing a capsule, and then filled in a gelatin capsule to prepare a capsule.
상기 성분들을 혼합한 후 30% 에탄올 100 mL를 첨가하여 60℃에서 건조시켜 과립을 형성한 후 포에 충진하여 과립제를 제조한다.
After mixing the above components, 100 mL of 30% ethanol is added, and the mixture is dried at 60 ° C to form granules, which are filled in a capsule to prepare granules.
상기 성분들을 혼합한 후 통상의 환제의 제조방법에 따라 제조한다.
After mixing the above components, they are prepared according to the usual production method of pills.
통상의 주사제 제조방법에 따라 1 앰플당 (2 mL)가 되도록 상기 성분을 혼합하여 제조한다.
(2 mL) per 1 ampoule according to a conventional injection preparation method.
통상의 액제 제조방법에 따라 정제수에 상기 성분을 용해시키고, 적절한 향을 가한 다음 병에 충진하여 멸균시켜 제조한다.
Dissolving the above components in purified water according to a usual liquid preparation method, adding an appropriate fragrance, filling the bottle and sterilizing it.
제법 quite
A의 유상부와 B의 수상부를 각각 70℃로 가열하여 완전 용해한다. A상을 B상에 부가하여 유화기로 유화한다. 유화물을 열교환기를 이용하여 냉각하여 크림을 얻었다.
The oil phase part of A and the water phase part of B are completely melted by heating them at 70 占 폚. Add phase A to phase B and emulsify with emulsifier. The emulsion was cooled with a heat exchanger to obtain a cream.
제법quite
제조예 1에 준하여 유액을 얻었다.
A milky lotion was obtained according to Production Example 1.
제법 quite
A의 알콜상을 B의 수상에 첨가하고, 가용화하여 화장수를 얻었다.
The alcohol phase of A was added to the aqueous phase of B and solubilized to obtain a lotion.
제법quite
상기 처방으로 상법에 의해 유액을 제조했다.
As the prescription, the emulsion was prepared by a commercial method.
제법quite
상기 처방으로 상법에 의해 화장수를 제조했다.
Lotions were prepared by the commercial method under the above prescription.
제법quite
상기 처방으로 상법에 의해 크림을 제조했다.
The cream was prepared by the above-mentioned procedure in accordance with the above-mentioned prescription.
Claims (20)
[화학식]
A pharmaceutical composition for preventing or treating contact dermatitis comprising, as an active ingredient, a bellflower extract containing Platycodin D represented by the following formula (1):
[Chemical Formula]
상기 약학적 조성물은 가려움증을 완화하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물.
The method according to claim 1,
A pharmaceutical composition for preventing or treating contact dermatitis, wherein said pharmaceutical composition alleviates itching.
상기 약학적 조성물은 염증반응을 억제하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물.
The method according to claim 1,
Wherein said pharmaceutical composition inhibits an inflammatory reaction.
상기 약학적 조성물은 부종을 억제하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물.
The method according to claim 1,
Wherein said pharmaceutical composition inhibits edema. ≪ RTI ID = 0.0 > 21. < / RTI >
상기 접촉성 피부염은 외부물질과의 접촉에 의한 접촉성 피부염인 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물.
The method according to claim 1,
Wherein the contact dermatitis is contact dermatitis due to contact with an external substance.
상기 약학적 조성물 중 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물은 전체 약학적 조성물 중량의 0.0001 내지 0.1 중량%인 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물.
The method according to claim 1,
A pharmaceutical composition for preventing or treating contact dermatitis, wherein the bellflower extract containing Platycodin D in the pharmaceutical composition is 0.0001 to 0.1% by weight of the total pharmaceutical composition.
플라티코딘 D(Platycodin D) 함유 도라지 추출물은 도라지(Platycodon grandiflorum)를 물 또는 탄소수 1 내지 4의 저급 알코올로 추출하고 발효시킨 후 원심분리하여 고형분을 제거한 후, 농축, 동결건조 과정을 거쳐 제조된 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 약학적 조성물.
The method according to claim 1,
Platycodin D-containing bellflower extract is prepared by extracting Platycodon grandiflorum with water or a lower alcohol having 1 to 4 carbon atoms, fermenting it, centrifuging it to remove solid content, concentrating it, and lyophilizing it ≪ / RTI > or a pharmaceutically acceptable salt thereof, for the prophylaxis or treatment of contact dermatitis.
농축, 동결건조 시키는 단계를 포함하는 접촉성 피부염 예방 또는 치료용 플라티코딘 D 함유 도라지 추출물을 제조하는 방법.
Platycodon grandiflorum ) is extracted with water or a lower alcohol having 1 to 4 carbon atoms, fermented, and centrifuged to remove solid matter; And
Concentrating and lyophilizing the platycodin D-containing bellflower extract for preventing or treating contact dermatitis.
저급 알코올은 메탄올 또는 에탄올인 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 플라티코딘 D 함유 도라지 추출물을 제조하는 방법.
9. The method of claim 8,
Wherein the lower alcohol is methanol or ethanol. ≪ RTI ID = 0.0 > 11. < / RTI >
[화학식 1]
An external preparation for skin for preventing or treating contact dermatitis comprising, as an active ingredient, a bellflower extract containing Platycodin D represented by the following formula (1)
[Chemical Formula 1]
상기 약학적 조성물은 가려움증을 완화하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 피부외용제.
11. The method of claim 10,
Wherein said pharmaceutical composition alleviates itching. ≪ RTI ID = 0.0 > 11. < / RTI >
상기 약학적 조성물은 염증반응을 억제하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 피부외용제.
11. The method of claim 10,
Wherein said pharmaceutical composition inhibits an inflammatory reaction. ≪ RTI ID = 0.0 > 11. < / RTI >
상기 약학적 조성물은 부종을 억제하는 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 피부외용제.
11. The method of claim 10,
Wherein the pharmaceutical composition inhibits edema. ≪ RTI ID = 0.0 > 11. < / RTI >
상기 피부외용제는 연고제, 크림제, 로숀제, 액제, 드레싱제, 패취제, 수포제, 테이프제, 연무제, 외용산제 및 스프레이제로 이루어진 그룹으로부터 선택되는 어느 하나인 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 피부외용제.
11. The method of claim 10,
Wherein the external preparation for skin is any one selected from the group consisting of an ointment, a cream, a lotion, a liquid, a dressing, a patch, a foaming agent, a tape agent, an aerosol agent, Therapeutic skin external preparation.
상기 약학적 조성물 중 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물은 전체 약학적 조성물 중량의 0.0001 내지 0.1 중량%인 것을 특징으로 하는 접촉성 피부염 예방 또는 치료용 피부외용제.
11. The method of claim 10,
Wherein the platycodin D-containing platycodone extract is 0.0001 to 0.1 wt% of the total weight of the pharmaceutical composition.
[화학식 1]
A health functional food for improving or alleviating contact dermatitis comprising, as an active ingredient, a bellflower extract containing platycodin D represented by the following formula 1:
[Chemical Formula 1]
상기 건강기능식품은 가려움증을 완화하는 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 건강기능식품.
17. The method of claim 16,
Wherein said health functional food alleviates itching. ≪ RTI ID = 0.0 > 18. < / RTI >
상기 건강기능식품은 염증반응을 완화하는 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 건강기능식품.
17. The method of claim 16,
Wherein said health functional food alleviates an inflammatory reaction.
상기 건강기능식품은 부종을 완화하는 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 건강기능식품.
17. The method of claim 16,
Wherein said health functional food alleviates edema. ≪ RTI ID = 0.0 > 18. < / RTI >
상기 건강기능식품 중 플라티코딘 D(Platycodin D)를 함유하는 도라지 추출물 파우더는 전체 건강기능식품 중량의 0.001 내지 1중량%인 것을 특징으로 하는 접촉성 피부염 개선 또는 완화용 건강기능식품.
17. The method of claim 16,
Wherein said Platycodin D-containing Platycodin powder is 0.001 to 1% by weight of the total weight of the health functional food.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130009767A KR20140096771A (en) | 2013-01-29 | 2013-01-29 | Pharmaceutical composition comprising Platycodin grandiflorum extract containing platycodin D |
| PCT/KR2014/000408 WO2014119859A1 (en) | 2013-01-29 | 2014-01-14 | Pharmaceutical composition of platycodon grandiflorum extract including platycodin d which is for preventing or treating skin diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130009767A KR20140096771A (en) | 2013-01-29 | 2013-01-29 | Pharmaceutical composition comprising Platycodin grandiflorum extract containing platycodin D |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140096771A true KR20140096771A (en) | 2014-08-06 |
Family
ID=51744556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130009767A KR20140096771A (en) | 2013-01-29 | 2013-01-29 | Pharmaceutical composition comprising Platycodin grandiflorum extract containing platycodin D |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20140096771A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210026739A (en) | 2019-09-02 | 2021-03-10 | 한도라지영농조합법인 | Method for preparing bellflower root powder containing bellflower root extract as active ingredient |
| CN114929238A (en) * | 2020-01-23 | 2022-08-19 | 株式会社Lg生活健康 | Composition for preventing alopecia and promoting hair growth |
-
2013
- 2013-01-29 KR KR1020130009767A patent/KR20140096771A/en not_active Application Discontinuation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210026739A (en) | 2019-09-02 | 2021-03-10 | 한도라지영농조합법인 | Method for preparing bellflower root powder containing bellflower root extract as active ingredient |
| CN114929238A (en) * | 2020-01-23 | 2022-08-19 | 株式会社Lg生活健康 | Composition for preventing alopecia and promoting hair growth |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9603789B2 (en) | Composition containing a natural extract | |
| JP2006111560A (en) | Ceramide synthesis promoter | |
| WO2008072941A1 (en) | Compositions comprising compounds of natural origin for damaged skin | |
| KR101367423B1 (en) | Pharmaceutical composition and cosmetic compostion for improving skin condition and preparation method thereof | |
| JP2006124350A (en) | Nmf production promoter | |
| KR101516063B1 (en) | Skin moisturizing composition comprising Platycodin grandiflorum containing platycodin D | |
| KR100961217B1 (en) | Fermented material of opunita humifusa for the prevention and treatment of allergic contact dermatitis | |
| KR101525691B1 (en) | Cosmetic composition containing leonurus sibiricus extract for improving skin allergy | |
| JP2011178770A (en) | Composition inhibiting skin pigmentation and application of the same | |
| KR102101949B1 (en) | A skin-care agent or cosmetics containig Antrodia camphorata fruit body extract or Antrodia camphorata mycelium extract | |
| KR101419588B1 (en) | Composition for Moisturizing Skin Comprising Ginseng Oil as Active Ingredient | |
| KR20190064714A (en) | Anti-inflammatory agent containing backhousia citriodora extract | |
| KR20140096771A (en) | Pharmaceutical composition comprising Platycodin grandiflorum extract containing platycodin D | |
| KR101986629B1 (en) | Composition for anti-pruritic comprising grape pruning stem extract as effective component | |
| JP2006257060A (en) | TESTOSTERONE 5alpha-REDUCTASE INHIBITOR AND AGENT FOR HAIR AND SKIN CARE PREPARATION FOR DERMAL USE FORMULATED WITH THE SAME | |
| KR101623682B1 (en) | Pharmaceutical composition comprising eriodictyol or its pharmaceutically acceptable salts as an active ingredient for preventing or treating contact dermatitis | |
| JP2015124189A (en) | Sebum synthesis inhibitor | |
| KR102012366B1 (en) | Composition for whitening comprising Withania somnifera callus extract | |
| KR101702621B1 (en) | Anti-inflammatory agent containing phlox subulata extract | |
| KR20130090071A (en) | Selective extracted method for acne-prone skin antibacterial ingredient using supercuritical fluid from ginger | |
| JP5657723B2 (en) | Prevention or suppression of skin photoaging | |
| KR20180055137A (en) | Composition comprising Rhus Semialata extract as active ingredient | |
| JP2021095370A (en) | Panax ginseng seeds treated by method comprising steam heat treatment step and/or skin external or internal formulation containing extract thereof | |
| KR20160038102A (en) | Composition for treating, improving or preventing allergic disease containing extract of Triticum aestivum Lamarck | |
| KR20160061601A (en) | Cosmetic composition and pharmaceutical composition containing the extract of Corchorus olitorius L, ginko and chlorella |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E601 | Decision to refuse application |